Radcliffe Capital Management’s LAVA Medtech Acquisition Corp. Warrants LVACW Stock Holding History

Radcliffe Capital Management’s Portfolio LVACW Stock Details LVACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-69,664	Closed	-$5.84K	–	658
2023 Q1	$5.84K	Hold	69,664	–	–	﹤0.01%	604
2022 Q4	$714K	Hold	69,664	–	–	0.02%	744
2022 Q3	$700K	Buy	69,664 +17,804	+34%	+$3.13K	0.02%	1014
2022 Q2	$517K	Hold	51,860	–	–	0.01%	1108
2022 Q1	$517K	Buy	51,860 +1,860	+4%	+$753	0.01%	1113
2021 Q4	$500K	Buy	+50,000	New	+$25.7K	0.01%	968

Radcliffe Capital Management's LVACW Position: Q2 2023 in Review

Radcliffe Capital Management sold out of LAVA Medtech Acquisition Corp. Warrants (LVACW) in Q2 2023, closing a stake of 69,664 shares — an estimated $5.84K sold.

Radcliffe Capital Management first reported a position in LVACW in Q4 2021 and held it in 6 quarters. The position peaked at $714K in Q4 2022. 0 funds tracked by Wall St. Rank hold LVACW as of Q2 2023.

Radcliffe Capital Management reported no remaining LAVA Medtech Acquisition Corp. Warrants position as of Q2 2023 after selling out during the quarter.
Radcliffe Capital Management sold 69,664 LAVA Medtech Acquisition Corp. Warrants shares in Q2 2023, an estimated $5.84K.
Radcliffe Capital Management first reported a position in LAVA Medtech Acquisition Corp. Warrants in Q4 2021 and held it in 6 quarters.
Radcliffe Capital Management's LAVA Medtech Acquisition Corp. Warrants position peaked at $714K in Q4 2022.
0 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Warrants as of Q2 2023.

Based on Radcliffe Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.